REDWOOD CITY, Calif. - Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotech company specializing in antibody therapies, announced plans to initiate a Phase 1b/2a clinical trial for its drug briquilimab in asthma patients, expected to begin in Q4 2024. This study aims to explore the drug's potential to deplete mast cells, which are known to play a key role in inflammatory responses associated with asthma.
The company's decision follows the presentation of preclinical data at the American Academy of Allergy, Asthma, and Immunology annual meeting, where briquilimab demonstrated effectiveness in reducing mast cells and preventing allergen-induced asthmatic responses in a c-Kit Mouse™ model.
Briquilimab, a monoclonal antibody targeting c-Kit (CD117), has been previously studied in over 145 participants, showing promise as a treatment for various conditions, including chronic urticaria and myelodysplastic syndromes (MDS), as well as a conditioning agent for stem cell transplants in diseases such as sickle cell disease (SCD) and severe combined immunodeficiency (SCID).
The company's President and CEO, Ronald Martell, expressed optimism about briquilimab's potential impact on asthma disease control, particularly for patients who are not responsive to current biologic agents.
Jasper Therapeutics is set to host a Key Opinion Leader (KOL) webinar on May 20, 2024, featuring Professor Joshua Boyce, M.D., who will discuss the current asthma treatment landscape and the potential role of briquilimab as a therapeutic option. The company's leadership team will also review the preclinical data and discuss the upcoming clinical development plans for the drug in asthma.
This news is based on a press release statement from Jasper Therapeutics, Inc.
InvestingPro Insights
As Jasper Therapeutics, Inc. (NASDAQ:JSPR) gears up for its Phase 1b/2a clinical trial of briquilimab, potential investors and stakeholders are closely monitoring the company's financial health and market performance. Recent data from InvestingPro paints a nuanced picture of the company's current standing. With a market capitalization of approximately $321.77 million, Jasper Therapeutics is a player in the biotech industry that's worth watching. However, the company's P/E ratio stands at -3.40, reflecting that it is not currently generating profits—a common scenario for many biotech firms in their developmental stages.
InvestingPro Tips suggest that while Jasper Therapeutics holds more cash than debt on its balance sheet, indicating some financial stability, the company is quickly burning through cash, which may raise concerns about its long-term funding capabilities. This is particularly relevant as the company embarks on new clinical trials, which are often capital-intensive. Additionally, the company's stock has experienced substantial volatility, with a significant price uptick over the last six months, signaling a 224.71% return. Yet, it's essential to note that analysts do not anticipate the company will be profitable this year, and the stock has fared poorly over the last month with a -23.05% return.
For those considering an investment in Jasper Therapeutics, it's worth exploring the full list of 10 additional InvestingPro Tips available at https://www.investing.com/pro/JSPR. These tips provide deeper insights that could help in making a more informed decision. And to enhance your InvestingPro experience, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.